title: Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact.
abstract: OBJECTIVE
  Two human papillomavirus (HPV) vaccines are available to prevent cervical cancer. One early measure of HPV vaccine impact would be a reduction in vaccine-related HPV types (HPV 6, 11, 16, or 18, or HPV 16, 18) in cervical samples from young women. We aimed to assess feasibility of specimen collection and baseline HPV prevalence in an integrated healthcare delivery system.
  
  
  METHODS
  Residual cervical specimens collected during routine cervical cancer screening (2006-2008) were retained consecutively from eligible females aged 11-29 years, stratified by age group. Specimens were evaluated for 37 HPV genotypes using the Roche Linear Array assay.
  
  
  RESULTS
  Of 10,124 specimens submitted, 10,103 (99 %) were adequate for HPV testing. Prevalence of HPV 6, 11, 16, or 18 genotype was 11.4 % overall and was the highest in the youngest age group (18.1 % in the 11-19-year-olds, 12.5 % in the 20-24-year-olds, and 7.0 % in the 25-29-year-olds).
  
  
  CONCLUSIONS
  HPV types 6, 11, 16, or 18 prevalence could be measured over time to assess early HPV vaccine impact using residual specimens from an integrated healthcare delivery system, particularly if sampling focused on young women.
authors.affiliation: Division of STD Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, GA 30333, USA. dde9@cdc.gov
authors.forename: Eileen F
authors.initials: EF
authors.lastname: Dunne
authors.forename: Nicola P
authors.initials: NP
authors.lastname: Klein
authors.forename: Allison L
authors.initials: AL
authors.lastname: Naleway
authors.forename: Roger
authors.initials: R
authors.lastname: Baxter
authors.forename: Sheila
authors.initials: S
authors.lastname: Weinmann
authors.forename: Karen
authors.initials: K
authors.lastname: Riedlinger
authors.forename: Barbara
authors.initials: B
authors.lastname: Fetterman
authors.forename: Martin
authors.initials: M
authors.lastname: Steinau
authors.forename: Mariela Z
authors.initials: MZ
authors.lastname: Scarbrough
authors.forename: Julianne
authors.initials: J
authors.lastname: Gee
authors.forename: Lauri E
authors.initials: LE
authors.lastname: Markowitz
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Unger
mesh_terms: D000293:Adolescent; D000328:Adult; D052685:Alphapapillomavirus / Q000235:genetics / Q000302:isolation & purification*; D002140:California / Q000453:epidemiology; D002648:Child; D019033:Delivery of Health Care, Integrated / Q000379:methods*; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000235:genetics; D015995:Prevalence; D012307:Risk Factors; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology*; D055815:Young Adult
chemical_list: D053918:Papillomavirus Vaccines